Identification of metastasis-suppressive microRNAs in primary melanoma

Journal of the National Cancer Institute

Volumn 107, Issue 3, 2015, Pages

  Hanniford, Doug ^a   Segura, Miguel F ^a   Zhong, Judy ^a,b   Philips, Elliot ^a   Jirau Serrano, Xavier ^a   Darvishian, Farbod ^a   Berman, Russell S ^a,c   Shapiro, Richard L ^a,c   Pavlick, Anna C ^a,b   Brown, Brian ^d   Osman, Iman ^a,b   Hernando, Eva ^a  

^a Interdisciplinary Melanoma Cooperative Group   (United States)

^b Department of Environmental Medicine ^*  (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN RELATED PROTEIN 2-3 COMPLEX; ANTIMETASTATIC AGENT; CORTACTIN; MICRORNA; MICRORNA 211; MICRORNA 382; MICRORNA 516B; MICRORNA 708; RAC1 PROTEIN; UNCLASSIFIED DRUG; ARPC2 PROTEIN, HUMAN; CTTN PROTEIN, HUMAN; MIRN382 MICRORNA, HUMAN; MIRN516 MICRORNA, HUMAN; RAC1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CELL INVASION ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; MELANOMA CELL; MELANOMA METASTASIS; METASTASIS INHIBITION; METASTATIC MELANOMA; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR INVASION; TUMOR RECURRENCE; TUMOR VOLUME; CHEMISTRY; DISEASE COURSE; ISOLATION AND PURIFICATION; PATHOLOGY; SECONDARY; SKIN TUMOR; TUMOR CELL LINE;

ACTIN-RELATED PROTEIN 2-3 COMPLEX; CELL LINE, TUMOR; CORTACTIN; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICRORNAS; RAC1 GTP-BINDING PROTEIN; SKIN NEOPLASMS;

EID: 84927172464     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju494     Document Type: Article

References (60)

1. Gupta G, Massagu?J. Cancer metastasis: building a framework. Cell. 2006;127:(4)679-695.
2. Nguyen D, Massagu?J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007;8(5):341-352.
3. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006;20(16):2149-82.
4. Tsao H, Atkins M. Management of cutaneous melanoma. New Engl J Med. 2004;351(10):998-1012.
5. Piris A, Mihm M, Duncan L. AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol. 2011;38(5):394-400.
6. Balch C, Gershenwald J, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
7. Azzola M, Shaw H, Thompson J, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97(6):1488-1498.
8. Schmid-Wendtner M, Baumert J, Schmidt M, et al. Prognostic index for cutaneous melanoma: an analysis after follow-up of 2715 patients. Melanoma Res. 2001;11(6):619-626.
9. Leiter U, Buettner P, Eigentler T, et al. Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33, 384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol. 2012;66(1):37-45.
10. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635-3648.
11. Singh D, Febbo P, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002;1(2):203-209.
12. Glinsky G, Glinskii A, Stephenson A, et al. Gene expression profiling predicts clinical outcome of prostate cancer. J Clinical Invest. 2004;113(6):913-923.
13. van 't Veer L, Dai H, van de Vijver M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-536.
14. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med. 2004;351(27):2817-2826.
15. Beer D, Kardia S, Huang C-C, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8(8):816-824.
16. Rosenwald A, Wright G, Chan W, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Engl J Med. 2002;346(25):1937-1947.
17. Shipp M, Ross K, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68-74.
18. Yeoh E-J, Ross M, Shurtleff S, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1(2):133-143.
19. Latil A, Bi?he I, Ch?e L, et al. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. Clin Cancer Res. 2003;9(15):5477-5485.
20. Ramaswamy S, Ross K, Lander E, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33(1):49-54.
21. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522-531.
22. Gaziel-Sovran A, Segura M, Di Micco R, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell. 2011;20(1):104-118.
23. Levy C, Khaled M, Iliopoulos D, et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell. 2010;40(5):841-849.
24. Segura M, Hanniford D, Menendez S, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA. 2009;106(6):1814-1819.
25. Pencheva N, Tran H, Buss C, et al. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell. 2012;151(5):1068-1082.
26. Elson-Schwab I, Lorentzen A, Marshall C. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PloS One. 2010;5(10), pii:e13176.
27. Herlyn D, Iliopoulos D, Jensen PJ, et al. In vitro properties of human melanoma cells metastatic in nude mice. Cancer Res. 1990;50(8):2296-2302.
28. Chi SW, Zang JB, Mele A, et al. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature. 2009;460(7254):479-486.
29. Hafner M, Landthaler M, Burger L, et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell. 2010;141(1):129-141.
30. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15-20.
31. Yang J-H, Li J-H, Shao P, et al. starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res. 2011;39(Database issue):D202-209.
32. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1-13.
33. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
34. Ayala I, Baldassarre M, Giacchetti G, et al. Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation. J Cell Science. 2008;121(Pt 3):369-378.
35. Ren G, Crampton M, Yap A. Cortactin: Coordinating adhesion and the actin cytoskeleton at cellular protrusions. Cell Motility Cytoskeleton. 2009;66(10):865-873.
36. Weed S, Parsons J. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene. 2001;20(44):6418-6434.
37. Mullokandov G, Baccarini A, Ruzo A, et al. High-throughput assessment of microRNA activity and function using micro-RNA sensor and decoy libraries. Nat Methods. 2012;9(8):840-846.
38. Hsu MY, Elder DE, Herlyn M. Melanoma: The Wistar Melanoma (WM) Cell Lines. In: Masters JRW, Palsson B, eds. Human Cell Culture. Netherlands: Springer; 1999, 259-274.
39. Xu Y, Brenn T, Brown E, et al. Differential expression of micro-RNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br J Cancer. 2012;106(3):553-561.
40. Boyle G, Woods S, Bonazzi V, et al. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res. 2011;24(3):525-537.
41. Mazar J, DeYoung K, Khaitan D, et al. The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PloS One. 2010;5(11):e13779.
42. Perou C, S?lie T, Eisen M, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
43. Scott K, Nogueira C, Heffernan T, et al. Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell. 2011;20(1):92-103.
44. Segura M, Belitskaya-L?y I, Rose A, et al. Melanoma Micro-RNA signature predicts post-recurrence survival. Clin Cancer Res. 2010;16(5):1577-1586.
45. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
46. Goley ED, Welch MD. The ARP2/3 complex: an actin nucleator comes of age. Nat Rev Mol Cell Biol. 2006;7(10):713-726.
47. Smith LG, Li R. Actin polymerization: riding the wave. Curr Biol. 2004;14(3):R109-R111.
48. Eden S, Rohatgi R, Podtelejnikov AV, et al. Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck. Nature. 2002;418(6899):790-793.
49. Murphy D, Courtneidge S. The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat Rev. Mol Cell Biol. 2011;12(7):413-426.
50. Weaver A. Invadopodia: specialized cell structures for cancer invasion. Clin Exp Metastasis. 2006;23(2):97-105.
51. Weaver A. Cortactin in tumor invasiveness. Cancer Lett. 2008;265:(2)157-166.
52. Clark E, Whigham A, Yarbrough W, et al. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 2007;67(9):4227-4235.
53. Cosen-Binker L, Kapus A. Cortactin: the gray eminence of the cytoskeleton. Physiology (Bethesda, MD). 2006;21:352-413.
54. Buday L, Downward J. Roles of cortactin in tumor pathogenesis. Biochim Biophys Acta. 2007;1775(2):263-273.
55. Li A, Ma Y, Yu X, et al. Rac1 drives melanoblast organization during mouse development by orchestrating pseudopod-driven motility and cell-cycle progression. Dev Cell. 2011;21(4):722-734.
56. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251-263.
57. Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44(9):1006-1014.
58. Li A, Ma Y, Jin M, et al. Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism. J Invest Dermatol. 2012;132(11):2610-2621.
59. Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485(7399):502-506.
60. Lindsay CR, Lawn S, Campbell AD, et al. P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun. 2011;2:555.